Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. February 02, 2018 Errata. October 01, 2018 ARTICLE CITATION DOI: 10.1200/JCO.2018.77.9637 Journal of Clinical Oncology - published online before print May 1, 2018 PMID: 29715055 Next-Generation Drugs Targeting the Cereblon Ubiquitin Ligase Sarah A. HolsteinxSarah A. HolsteinSearch for articles by this author, Jens HillengassxJens HillengassSearch for articles by this author, and Philip L. McCarthyxPhilip L. McCarthySearch for articles by this author Show More Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; and Jens Hillengass and Philip L. McCarthy, Roswell Park Comprehensive Cancer Center, Buffalo, NY https://doi.org/10.1200/JCO.2018.77.9637 First Page Full Text PDF Figures and Tables Supplements © 2018 by American Society of Clinical Oncology Companion Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial Errata Errata